Biomarkers are measurable biological signs in your body, such as blood pressure, blood sugar, or genes. They help doctors catch diseases early, choose the right treatments for your body, and track whether a medicine is working. Simply put, biomarkers act like road signs for your health.
Here is why biomarkers matter:
- Early Detection: They spot hidden health problems before you feel sick. For example, high albumin levels in urine detect kidney disease early.
- Personalized Care: They show which medicine will work best for your body. In cancer care, doctors use biomarker testing to find genetic changes to use targeted therapy.
- Tracking Progress: They let doctors measure how well a treatment is working. A simple blood test can show if a tumor is shrinking or if a disease is coming back.
- Safer Drugs: Scientists use biomarkers to develop and test new medicines faster and more safely
Why One Biomarker may not be Enough
- Multiple Ways of Working: Cell therapies, such as CAR-T and stem cell therapies, work through several processes simultaneously. These include directly killing cells, releasing healing signals, and staying active in the body. One marker can only measure one of these actions.
- Natural Differences: Cells are living and naturally different from each other. One biomarker cannot show changes in cell health, energy use, or harmful actions.
- Rules from Authorities: The FDA expects developers to use several combined methods to demonstrate that a therapy is consistent, reliable, and works as intended.
But cell-free DNA (cfDNA) alone is a great biomarker because it acts as a non-invasive, cost-effective, real-time liquid biopsy. By analyzing fragmented DNA circulating in bodily fluids, doctors can track organ injury, fetal health, and cancer without painful, expensive surgical biopsies.
Cell-free DNA (cfDNA) consists of small fragments of genetic material released by cells into the bloodstream. In cervical cancer, physicians detect human papillomavirus (HPV) cfDNA through liquid biopsy to aid early diagnosis, monitor treatment response, and identify recurrence.
When cells die, they release fragmented genetic material into the bloodstream, called cfDNA. Cancer cells also release DNA known as circulating tumor DNA (ctDNA). Discovered in 1948, cfDNA became widely used in medicine in the late 1990s and is now essential in cancer and prenatal testing.
How cfDNA Helps with Diagnosis
Instead of a tissue biopsy, physicians can analyze a blood sample for cfDNA to detect cancer-specific markers. This provides a non-invasive overview of disease status.
Here is why Cell-free DNA is so powerful:
- Non-Invasive: A simple blood draw or urine test replaces painful, risky surgical procedures.
- Cost-Effective: Measuring total cfDNA costs less than complex DNA sequencing to find specific mutations.
- Real-Time Tracking: cfDNA clears from the body quickly, with a half-life as short as 15 minutes. This gives doctors immediate feedback on patient response to treatment.
- Whole-Body Picture: Tumors and damaged organs shed cfDNA into the bloodstream. This provides a complete view of the body’s health rather than just one spot tested by a traditional biopsy.
Below is a brief overview of the primary medical applications of cfDNA and their timelines:
1. Cancer (Oncology)
- When recognized: The late 1990s to early 2000s.
- Significance: When cancer cells die, they release mutated DNA into the bloodstream. Physicians can detect these tumor markers through a blood test known as a liquid biopsy.
- Applications: Detecting early-stage cancers, such as lung and pancreatic cancer, and monitoring treatment effectiveness.
2. Pregnancy (Prenatal Testing)
- When recognized: 1997.
Why it matters: Fetal DNA can be detected in maternal blood, enabling non-invasive prenatal screening (NIPT). This allows doctors to safely check for genetic conditions like Down syndrome without putting the pregnancy at risk.
3. Autoimmune Diseases
- When recognized: 1966.
- Significance: Elevated cfDNA levels are associated with severe inflammation.
- Applications: Monitoring disease activity and flare-ups in patients with lupus.
Cervical cancer is a leading cancer in many Asian countries, mainly due to under-resourced health systems programs.
HPV Connection: Nearly all cervical cancers are caused by human papillomavirus (HPV), which has distinct DNA. Specific Markers: Physicians can detect this viral DNA in a patient’s blood, providing a clear indicator of disease.
Real-Time Tracking: Cancer DNA rapidly clears from the bloodstream once eliminated, allowing physicians to closely monitor treatment effectiveness.
Detecting Relapse: The eLife Study on HPV cfDNA found that monitoring HPV cfDNA can identify cancer recurrence months before it appears on imaging scans.
Cervical cancer is the second most common cancer among Indian women. The disease disproportionately affects low- and middle-income regions due to several key factors:
- HPV Infections: Persistent infection with high-risk HPV strains (specifically HPV 16 and HPV 18) causes nearly all cervical cancers.
- Poverty and Education: Lack of money and health education creates barriers to accessing medical care.
- Limited Screening: India lacks a systematic, nationwide screening program. As a result, most women are diagnosed at advanced stages when the disease is much harder to treat.
- Low Vaccination: Preventive HPV vaccines have historically been unavailable or too expensive for the general public, though the Indian government is expanding rollout campaigns.
- Cultural Barriers: Gender inequality and deep-seated social stigmas create severe hurdles. Many women require familial consent to seek care, and some fear social shame if they have a reproductive health issue.